View Financial HealthChugai Pharmaceutical 배당 및 자사주 매입배당 기준 점검 4/6Chugai Pharmaceutical 수익으로 충분히 충당되는 현재 수익률 1.77% 보유한 배당금 지급 회사입니다.핵심 정보1.8%배당 수익률-0.0007%자사주 매입 수익률총 주주 수익률1.8%미래 배당 수익률2.4%배당 성장률18.4%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향44%최근 배당 및 자사주 매입 업데이트공시 • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.모든 업데이트 보기Recent updates공시 • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.공시 • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.공시 • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.공시 • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026공시 • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.공시 • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.공시 • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.공시 • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.공시 • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025공시 • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.공시 • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024공시 • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024공시 • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.공시 • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.공시 • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.공시 • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023공시 • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: CHGC.F 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: CHGC.F 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Chugai Pharmaceutical 배당 수익률 vs 시장CHGC.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CHGC.F)1.8%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (CHGC.F) (최대 3년)2.4%주목할만한 배당금: CHGC.F 의 배당금( 1.77% )은 US 시장에서 배당금 지급자의 하위 25%( 1.42% )보다 높습니다.고배당: CHGC.F 의 배당금( 1.77% )은 US 시장에서 배당금 지급자의 상위 25%( 4.25% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 44.4% )로 CHGC.F 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 65.4% )로 CHGC.F 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 00:24종가2026/06/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Chugai Pharmaceutical Co., Ltd.는 27명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research24명의 분석가 더 보기
공시 • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.
공시 • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.
공시 • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.
공시 • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.
공시 • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
공시 • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.
공시 • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.
공시 • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.
공시 • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.
공시 • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025
공시 • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.
공시 • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024
공시 • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024
공시 • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
공시 • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
공시 • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.
공시 • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023
공시 • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023